Apellis Pharmaceuticals, Inc. (APLS) P/E Ratio History
Historical price-to-earnings valuation from 2025 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
The current P/E is 80% above its 5-year average of 64.7x. Over the past five years, APLS's P/E has ranged from a low of 64.7x to a high of 64.7x, placing the current valuation at the 100th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, APLS trades at a 392% premium to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, APLS commands a significant premium over the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our APLS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Immunology and Inflammation Therapies peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
ARGXargenx SE | $47B | 60.0 | -Best | +348% |
TGTXTG Therapeutics, Inc. | $5B | 200.6 | -Best | +76% |
KNSAKiniksa Pharmaceuticals, Ltd. | $3B | 59.3 | -Best | +225% |
APLSApellis Pharmaceuticals, Inc. | $3B | 116.4 | -Best | +111% |
GLPGGalapagos N.V. | $2B | 5.9Lowest | -Best | +333% |
AUPHAurinia Pharmaceuticals Inc. | $2B | 6.8 | -Best | +5167%Best |
GYREGyre Therapeutics, Inc. | $711M | 164.8 | -Best | +104% |
RIGLRigel Pharmaceuticals, Inc. | $615M | 35.1 | -Best | +169% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $22.63 | $0.35 | 64.7x | +0% |
Average P/E for displayed period: 64.7x
See APLS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs APLS Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare APLS vs AGIO
See how APLS stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is APLS stock overvalued or undervalued?
APLS trades at 116.4x P/E, above its 5-year average of 64.7x. The 100th percentile ranking indicates a premium to historical valuation.
How does APLS's valuation compare to peers?
Apellis Pharmaceuticals, Inc. P/E of 116.4x compares to sector median of 23.7x. The premium reflects expected growth above peers.
What is APLS's PEG ratio?
APLS PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2025-2025.